Human Papillomavirus type distribution in Vulval Intraepithelial Neoplasia determined using PapilloCheck DNA microarray

Dean Bryant, Nirmala Rai, Gareth Lloyd Rowlands, Sam Hibbitts, Joanne Jones, Amanda Tristram, Alison Fiander, Ned Powell

► To cite this version:

Dean Bryant, Nirmala Rai, Gareth Lloyd Rowlands, Sam Hibbitts, Joanne Jones, et al.. Human Papillomavirus type distribution in Vulval Intraepithelial Neoplasia determined using PapilloCheck DNA microarray. *Journal of Medical Virology*, 2011, 83 (8), pp.1358. 10.1002/jmv.22107 . hal-00645108

HAL Id: hal-00645108

<https://hal.science/hal-00645108>

Submitted on 26 Nov 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Human Papillomavirus type distribution in Vulval Intraepithelial Neoplasia determined using PapilloCheck DNA microarray

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-11-2313.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	22-Mar-2011
Complete List of Authors:	Bryant, Dean; School of Medicine, Cardiff University, Obstetrics and Gynaecology Rai, Nirmala; School of Medicine, Cardiff University, Obstetrics and Gynaecology Rowlands, Gareth; University Hospital of Wales, Pathology Hibbitts, Sam; School of Medicine, Cardiff University, Obstetrics and Gynaecology Jones, Joanne; School of Medicine, Cardiff University, Obstetrics and Gynaecology Tristram, Amanda; School of Medicine, Cardiff University, Obstetrics and Gynaecology Fiander, Alison; School of Medicine, Cardiff University, Obstetrics and Gynaecology Powell, Ned; School of Medicine, Cardiff University, Obstetrics and Gynaecology
Keywords:	HPV, Human papillomavirus, VIN, Vulval intraepithelial neoplasia, Papillocheck

SCHOLARONE™
Manuscripts

1 **Human Papillomavirus type distribution in Vulval Intraepithelial Neoplasia**
2 **determined using PapilloCheck DNA microarray**

4 Dean Bryant, Nirmala Rai, Gareth Rowlands, Sam Hibbitts, Joanne Jones, Amanda
5 Tristram, Alison Fiander, Ned Powell*

7 HPV Research Group, Obstetrics and Gynaecology, School of Medicine, Cardiff
8 University, CF14 4XN

10 *Correspondence to:

11 Dr Ned Powell

12 Obstetrics and Gynaecology

13 School of Medicine

14 Cardiff University

15 Heath Park

16 CF14 4XN

17 Email: powelling@cf.ac.uk

19 Short title: HPV type distribution in vulval intraepithelial neoplasia

Abstract

Vulval intraepithelial neoplasia is a precursor of vulval carcinoma, and is frequently associated with Human Papillomavirus (HPV) infection. Estimates of HPV prevalence in vulval intraepithelial neoplasia vary widely in the UK. The objective of this study was to assess HPV infection in a sample of women with vulval intraepithelial neoplasia, confirmed histologically, and determine the proportion of disease associated with HPV types targeted by prophylactic HPV vaccines. HPV infection was assessed in biopsies from 59 patients using the Greiner Bio-One PapilloCheck® DNA chip assay. Valid results were obtained for 54 cases. HPV infection was present in 43 of the 54 cases (79.6%: 95% CI 67.1-88.2%). The most common HPV types were HPV 16 (33/54: 61.1%), HPV 33 (8/54: 14.8%), HPV 6 (5/54: 9.3 %) and HPV 42 (3/54: 5.6%). The mean age of HPV positive women was significantly less than the mean age of HPV negative women. This is the largest UK series of vulval intraepithelial neoplasia in which HPV type has been investigated, and 34/54 (63.0 %, 95% CI: 49.6-78.6 %) cases were associated with HPV 16/18, which are targeted by current prophylactic HPV vaccines.

Key words

HPV, Human papillomavirus, VIN, Vulval intraepithelial neoplasia, Papillocheck

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

39 **INTRODUCTION**

40 Vulval intraepithelial neoplasia is frequently a painful, distressing condition, and a
41 precursor lesion of invasive vulval carcinoma. In recent decades the incidence of
42 vulval intraepithelial neoplasia has increased, while the mean age of patients has
43 decreased. The incidence of vulval cancer rose by 17% between 1979 and 2001
44 [MacLean, 2004], with 996 new cases registered in England in 2000 [MacLean,
45 2006].
46 Human Papillomavirus (HPV) positivity in vulval intraepithelial neoplasia lesions is
47 reported in international meta-analyses as 84% with most cases attributable to HPV
48 type 16 [De Vuyst et al., 2009]. The most likely explanation for the increased
49 incidence of vulval intraepithelial neoplasia is the substantial rise in HPV infections
50 of the lower genital tract [Peto et al., 2004]; the lifetime risk of HPV infection being
51 estimated at up to 79% [Syrjanen et al., 1990].
52 The aim of this investigation was to identify HPV types present in vulval
53 intraepithelial neoplasia, confirmed histologically, using the Greiner Bio-One
54 PapilloCheck® DNA chip assay and determine the proportion of vulval intraepithelial
55 neoplasia potentially preventable by HPV prophylactic vaccination.

56

MATERIALS AND METHODS

Study population

The study population comprised women attending a specialist vulval intraepithelial neoplasia clinic at the University Hospital of Wales, Cardiff, UK between 2003 and 2009, with vulval intraepithelial neoplasia confirmed histologically, who gave written informed consent for a biopsy to be taken for research purposes. The study was approved by South Wales LREC (SMKW/EL/03/5178). 59 cases were investigated, with an age range of 22-82 years, and a mean age of 45.8 years. There were six cases of vulval intraepithelial neoplasia grade 1, two of vulval intraepithelial neoplasia grade 2, and fifty one cases of vulval intraepithelial neoplasia grade 3.

Sample collection and processing.

Separate biopsies were taken for histology and research use. The research biopsy was immediately placed in liquid based cytology medium (which fixed cells and preserved DNA). DNA was extracted from the research biopsy using the Qiagen QIAamp kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's instructions.

Pathology review

A recent review of vulval intraepithelial neoplasia histopathology recommended replacement of the vulval intraepithelial neoplasia 1/2/3 subdivisions with two categories reflecting the putative aetiology of the disease: usual vulval intraepithelial neoplasia (HPV-associated); and differentiated vulval intraepithelial neoplasia (associated with lichen sclerosis) [Sideri et al., 2005]. However, the existence of differentiated vulval intraepithelial neoplasia is disputed, and in practice this diagnosis is rarely made [McCluggage, 2009]. The histopathology of lesions in this study is

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

82 reported using both the vulval intraepithelial neoplasia 1/2/3 and usual/differentiated
83 classification. Pathology review was undertaken blind to HPV status by an
84 experienced Consultant Histopathologist with a special interest in gynaecological
85 pathology (GR).

86

87 **PapilloCheck® assay**

88 HPV infection was identified using the Greiner Bio-One Papillocheck® assay (Greiner
89 Bio-One GmbH, Frickenhausen, Germany), which enables simultaneous detection and
90 typing of 24 different HPV types in a single reaction (HPV 16, 18, 31, 33, 35, 39, 45,
91 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82, 6, 11, 40, 42, 43 & 44) . The assay uses
92 multiplex PCR with fluorescent primers to amplify a 350bp fragment of the E1 gene.
93 The PCR product is then hybridised to a PapilloCheck® DNA array, comprising 28
94 probes, each in 5 replicate spots. To identify false negatives the assay includes
95 amplification of the human ADAT1 gene. Hybridization is assessed using the
96 CheckScanner™ array reader. Amplification, hybridization, detection and
97 interpretation were performed according to the manufacturer’s instructions. A valid
98 result was defined as one which passed all of the PapilloCheck® internal controls
99 (including DNA adequacy, sample inhibition, and hybridisation).

100 Previous studies have confirmed the analytical [Dalstein et al., 2009; Jones et al.,
101 2009] and clinical validity [Halfon et al., 2009; Hesselink et al., 2009] of this assay in
102 large sample sets as compared to GP5+/6+, HC2 and Roche Linear Array. The assay
103 is certified within the European Union as an *in vitro* diagnostic for qualitative
104 detection of HPV in clinical specimens.

105

106

107 RESULTS

108 HPV type distribution

109 HPV type distribution, stratified by histology, is shown in Table I. Valid results were
110 obtained for 54 of the 59 cases. HPV infection was present in 43/54 cases (79.6%:
111 95% CI 67.1-88.2%). HPV 16 and/or 18 were present in 34/54 cases (63.0 %, 95%
112 CI: 49.6-78.6%). HPV 16 and/or 18 were the only types present in 26/54 cases (48%,
113 95% CI: 35.4-61.2%).
114 High Risk (HR) HPV types were present in 38 cases and Low Risk (LR) types in 9
115 cases; 4 cases contained both HR and LR types. Multiple HPV types were present in
116 10 cases; in these cases the distribution of types was: one vulval intraepithelial
117 neoplasia grade 1 sample contained HPV 18, 42 and 44/55; all other cases with
118 multiple types were vulval intraepithelial neoplasia 3 and the combinations of types
119 were: 3 cases with HPV 16 and 33; 2 cases with HPV 16 and 6; and one case each of
120 (16,18), (33, 42), (16, 31, 33), (16, 51). In the 5 cases where only LR types were
121 present, 3 were HPV 6 (histology: two cases of vulval intraepithelial neoplasia grade
122 3, and one vulval intraepithelial neoplasia grade 3 with well-differentiated carcinoma
123 and viral warts), 1 was HPV 40 (vulval intraepithelial neoplasia 1) and 1 contained
124 HPV 42 (vulval intraepithelial neoplasia 1).

126 HPV and age

127 HPV positive cases were aged 22-81 with a mean of 43.4 years. HPV negative cases
128 were aged 33-82 years with a mean of 54.9 years. The means of these groups were
129 significantly different (t test $p = 0.019$).

131 HPV and histology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

132 There was no significant correlation between HPV positivity and grade of lesion. Of
133 the HPV positive cases, 40/43 (93.0%) showed vulval intraepithelial neoplasia grade 2
134 or worse. This was slightly lower in HPV negative lesions, where 9/11 (81.8%)
135 showed vulval intraepithelial neoplasia grade 2 or worse, but this difference was not
136 significant (Fisher's $P = 0.266$).

137 There was no significant correlation between HPV type and histological grade;
138 however it was noticeable that all of the HPV 16 positive cases were associated with
139 vulval intraepithelial neoplasia 2 or worse, while a high risk type (HPV 18) was
140 identified in only 1/5 vulval intraepithelial neoplasia grade 1 cases with valid HPV
141 results.

142 Slides were available for pathology review for 54/59 cases. 52/54 cases were "Usual
143 vulval intraepithelial neoplasia"; 2/54 cases were "Probable Differentiated vulval
144 intraepithelial neoplasia". Both cases of probable Differentiated vulval intraepithelial
145 neoplasia were in HPV negative patients: one an 82 year old woman with vulval
146 intraepithelial neoplasia 3, the other a 61 year old woman with vulval intraepithelial
147 neoplasia 1 (but with a history of vulval cancer). Among the cases with valid HPV
148 results, 42/49 cases of usual vulval intraepithelial neoplasia were HPV positive
149 (85.7% 95%CI: 73.3-92.9%).

DISCUSSION

This is the largest UK series of vulval intraepithelial neoplasia in which HPV type has been determined. The main limitation of this study was the use of a self selected sample, i.e. women attending a specialist vulval intraepithelial neoplasia clinic. This might bias the sample towards women with persistent or recurrent disease, which might possibly result in some over-representation of more persistent types (HPV 16). A further limitation was the use of separate biopsies for pathology and HPV analysis; in practice both biopsies were immediately adjacent and cases were only included if both biopsies were part of the same macroscopically visible lesion. It is however theoretically possible that the research biopsy may not be representative of the diagnostic biopsy.

Several studies have investigated HPV prevalence in vulval intraepithelial neoplasia in the UK and estimate HPV positivity at 37.5 to 100%, with the proportion of HPV positive cases containing HPV 16 varying from 37.5 to 93.3% [Abdel-Hady et al., 2001; Baldwin et al., 2003; Daayana et al., 2010; Fiander et al., 2006; Gasco et al., 2002; Todd et al., 2002; Tristram and Fiander, 2005; Woo et al., 2007]. The sample size in these studies ranged from 8-29 cases. The sample size for the current study is larger, and the findings are more consistent with the overall results of a recent international meta-analysis, in which 84.0% of vulval intraepithelial neoplasia cases tested HPV positive (67.5% were HPV 16, 7.7% were HPV 33, and 4.6% were HPV 18) [De Vuyst et al., 2009]. The corresponding proportions in the current study were overall HPV positivity of 79.6% (61.1 % were positive for HPV 16, 14.8% for HPV 33, and 3.7% for HPV 18). These are also similar to a separate meta-analysis which

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

174 indicated an overall HPV positivity of 80.4% for vulval intraepithelial neoplasia 2/3
175 (HPV 16 present in 71.2%, HPV33 in 7.7% and HPV 18 in 5.5% [Smith et al., 2009]).
176 Patients who tested positive for HPV infection were significantly younger (by over 11
177 years on average) than those testing negative. This is consistent with HPV associated
178 disease being more common in younger women and vulval intraepithelial neoplasia
179 associated with lichen sclerosis being more common in older patients [Bonvicini et
180 al., 2005].
181 The finding that 85.7% of usual vulval intraepithelial neoplasia were HPV positive is
182 in accord with data previously reviewed [van de Nieuwenhof et al., 2008]. The 7 HPV
183 negative usual vulval intraepithelial neoplasia patients represent an interesting group;
184 it is not clear whether these patients are accounted for by mis-diagnosis of
185 differentiated vulval intraepithelial neoplasia (possibly due to sampling error), or
186 whether there is a subset of usual vulval intraepithelial neoplasia that is truly HPV
187 negative.
188
189 Three cases showing vulval intraepithelial neoplasia grade 2 or worse were associated
190 with a low risk HPV type alone (HPV6). One of these cases showed vulval
191 intraepithelial neoplasia grade 3 with well differentiated squamous cell carcinoma and
192 viral warts; it is possible that the warts were associated with the HPV 6 but the vulval
193 intraepithelial neoplasia and carcinoma were not. This apparent association between
194 high grade vulval intraepithelial neoplasia and LR HPV types runs contrary to the
195 suggestion that LR types cause only warts and low grade lesions. However an
196 association between LR HPV types and high grade disease was observed in the De
197 Vuyst meta analysis [De Vuyst et al., 2009] which reported approximately 5% of
198 vulval intraepithelial neoplasia 2/3 as linked to HPV 6.

199
200 HPV associated vulval intraepithelial neoplasia is most common in women in their
201 30's and 40's [Hart, 2001]. The incidence of VIN is approximately 5 per 100,000
202 women per year and is increasing [Joura, 2002]. HPV infection is endemic in the UK
203 with almost 30% of women in the 20-25 year age range now infected with a high risk
204 anogenital HPV type [Hibbitts et al., 2008]. Hence, in the short term, the number of
205 women affected by vulval intraepithelial neoplasia is likely to continue increasing.
206 HPV vaccination has been shown to be 100% effective in prevention of vulval
207 epithelial neoplasia 2/3 associated with HPV 16/18 in a per protocol population [Joura
208 et al., 2007]. In the UK vaccination of 12-13 year old girls against HPV 16/18
209 infection began in 2008. Hence it is likely to be 20 to 30 years before the effects of
210 this intervention become apparent in reduced incidence of vulval intraepithelial
211 neoplasia. Ultimately however, as HPV 16/18 were present in 63.0% of vulval
212 intraepithelial neoplasia, our data suggest that greater than half of vulval
213 intraepithelial neoplasia cases could be potentially prevented by vaccination.
214

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

215 **Acknowledgements**

216 DB is grateful for support by a Cancer Research Wales Studentship Award.

217 Funding: The consumables for this study were provided free of charge by Greiner

218 Bio-One GmbH, Frickenhausen, Germany.

219 Competing interests: None declared.

220

For Peer Review

References

- Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN. 2001. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. *Cancer Res* 61:192-196.
- Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC. 2003. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. *Clin Cancer Res* 9:5205-5213.
- Bonvicini F, Venturoli S, Ambretti S, Paterini P, Santini D, Ceccarelli C, Zerbini M, Musiani M. 2005. Presence and type of oncogenic human papillomavirus in classic and in differentiated vulvar intraepithelial neoplasia and keratinizing vulvar squamous cell carcinoma. *J Med Virol* 77:102-106.
- Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC. 2010. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. *Br J Cancer* 102:1129-1136.
- Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. 2009. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. *J Virol Methods* 156:77-83.
- De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. 2009. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer* 124:1626-1636.
- Fiander AN, Tristram AJ, Davidson EJ, Tomlinson AE, Man S, Baldwin PJ, Sterling JC, Kitchener HC. 2006. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. *Int J Gynecol Cancer* 16:1075-1081.
- Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, Dunne B, Gusterson B, Evans DJ, Crook T. 2002. Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. *Oncogene* 21:1876-1881.
- Halfon P, Benmoura D, Khiri H, Penaranda G, Blanc B, Riggio D, Sandri MT. 2009. Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck((R)) HPV-screening assay. *J Clin Virol.* 47:38-42.
- Hart WR. 2001. Vulvar intraepithelial neoplasia: historical aspects and current status. *Int J Gynecol Pathol* 20:16-30.
- Hesselink AT, Heideman DA, Berkhof J, Topal F, Pol RP, Meijer CJ, Snijders PJ. 2010. Comparison of the clinical performance of the PapilloCheck HPV detection with GP5+/6+-PCR-EIA in population-based cervical screening. *J Clin Microbiol.* 48:797-801
- Hibbitts S, Jones J, Powell N, Dallimore N, McRea J, Beer H, Tristram A, Fielder H, Fiander AN. 2008. Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study. *Br J Cancer* 99:1929-1933.
- Jones J, Powell NG, Tristram A, Fiander AN, Hibbitts S. 2009. Comparison of the PapilloCheck DNA microarray Human Papillomavirus detection assay with

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

269 Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer
270 set. *J Clin Virol* 45:100-104.

271 Joura EA. 2002. Epidemiology, diagnosis and treatment of vulvar intraepithelial
272 neoplasia. *Curr Opin Obstet Gynecol* 14:39-43.

273 Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA,
274 Garland SM, Harper DM, Tang GWK, Ferris DG, Steben M, Jones RW,
275 Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego
276 JW, Sattler C, Barr E, Paavonen J. 2007. Efficacy of a quadrivalent
277 prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-
278 particle vaccine against high-grade vulval and vaginal lesions: a combined
279 analysis of three randomised clinical trials. *The Lancet* 369:1693-1702.

280 MacLean AB. 2004. Vulval cancer: the past 100 years, and into the next century: the
281 Presidential Oration, British Society for the Study of Vulval Disease, 2002. *J*
282 *Obstet Gynaecol* 24:491-497.

283 MacLean AB. 2006. Vulval cancer: prevention and screening. *Best Pract Res Clin*
284 *Obstet Gynaecol* 20:379-395.

285 McCluggage WG. 2009. Recent developments in vulvovaginal pathology.
286 *Histopathology* 54:156-173.

287 Peto J, Gilham C, Fletcher O, Matthews FE. 2004. The cervical cancer epidemic that
288 screening has prevented in the UK. *Lancet* 364:249-256.

289 Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, Haefner H, Neill S.
290 2005. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology,
291 ISSVD Vulvar Oncology Subcommittee. *J Reprod Med* 50:807-810.

292 Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. 2009. Human
293 papillomavirus type-distribution in vulvar and vaginal cancers and their
294 associated precursors. *Obstet Gynecol* 113:917-924.

295 Syrjanen K, Hakama M, Saarikoski S, Vayrynen M, Yliskoski M, Syrjanen S, Kataja
296 V, Castren O. 1990. Prevalence, incidence, and estimated life-time risk of
297 cervical human papillomavirus infections in a nonselected Finnish female
298 population. *Sex Transm Dis* 17:15-19.

299 Todd RW, Etherington IJ, Luesley DM. 2002. The effects of 5% imiquimod cream on
300 high-grade vulval intraepithelial neoplasia. *Gynecol Oncol* 85:67-70.

301 Tristram A, Fiander A. 2005. Clinical responses to Cidofovir applied topically to
302 women with high grade vulval intraepithelial neoplasia. *Gynecol Oncol*
303 99:652-655.

304 van de Nieuwenhof HP, van der Avoort IA, de Hullu JA. 2008. Review of squamous
305 premalignant vulvar lesions. *Crit Rev Oncol Hematol* 68:131-156.

306 Woo YL, Damay I, Stanley M, Crawford R, Sterling J. 2007. The use of HPV Linear
307 Array Assay for multiple HPV typing on archival frozen tissue and DNA
308 specimens. *J Virol Methods* 142:226-230.

Histology	HPV Type								
	16	18	31	33	51	6	40	42	44/55*
VIN 1	0	1	0	0	0	0	1	2	1
VIN 2	1	0	0	0	0	1	0	0	0
VIN 3	32	1	1	8	1	4	0	1	0
Total	33	2	1	8	1	5	1	3	1
%	61.1	3.7	1.9	14.8	1.9	9.3	1.9	5.6	1.9

Table I. HPV type distribution within histological grade.

There were 10 cases showing multiple infection, hence the number of types identified is greater than the number of cases. Percentages indicate the proportion of cases that tested positive for a given type.

*the HPV 44 probe cross-hybridizes to HPV 55, hence these types are reported together.